Transdermal estradiol patches, commonly used by menopausal women, are emerging as a viable treatment option for prostate cancer, according to research published in the New England Journal of Medicine. The study suggests that estrogen patches are nearly as effective as traditional therapies in managing the disease, with notable differences in side effect profiles.
Prostate cancer is the most common cancer in U.S. men, excluding skin cancer, and the second-leading cause of cancer death among males. Experts estimate that one in six men will be diagnosed with the disease in their lifetime. This new research tested the efficacy of transdermal estradiol patches against luteinizing hormone–releasing hormone (LHRH) antagonists, a class of drugs that reduce testosterone production.
Treatment Efficacy and Side Effects
The three-year metastasis-free survival rate for patients using estrogen patches was 87.1%, compared to 85.9% for those receiving LHRH antagonists. Over five years, the metastasis-free survival was 81.1% for the estrogen patch group and 79.2% for the LHRH antagonist group. While these figures show slightly greater effectiveness for the estrogen patches, the differences in side effects were more pronounced.
Men using LHRH antagonists experienced hot flashes in 89% of cases, whereas only 44% of those using estrogen patches reported this symptom. Conversely, breast enlargement affected 85% of patients on estrogen patches, compared to 42% of those treated with LHRH agonists. These findings suggest that estrogen patches could offer a more tolerable treatment option for some prostate cancer patients.
Broader Applications and Risk Reduction
Beyond its potential role in prostate cancer treatment, estradiol is also recognized for its benefits to brain health, including enhancing neuroplasticity, reducing inflammation, and improving neural communication. This adds another dimension to the therapeutic potential of the hormone.
The study on estrogen patches is part of a broader landscape of advancing prostate cancer research. Recent investigations have explored other avenues, such as the anti-diabetic drug pioglitazone, which has shown promise in slowing cancer cell growth and preventing recurrence. Artificial intelligence is also making strides in diagnostics, with one UCLA study indicating an AI tool could identify prostate cancer with 84% accuracy, surpassing the 67% accuracy rate of physicians in the same study.
For men seeking to reduce their risk of prostate cancer, lifestyle factors are also considered. Data suggests that ejaculating 21 or more times per month may be associated with a 19-22% lower risk of developing the disease compared to men with lower ejaculation frequencies. Maintaining regular screening appointments also remains critical, as men who avoid screenings are significantly more likely to die from the disease. Despite these advancements, the U.S. is currently experiencing a shortage of estrogen patches, impacting availability for both menopausal women and potentially for prostate cancer treatment.